Law360, New York (October 02, 2009) -- Cordis Corp.'s and Boston Scientific Corp.'s opposing willfulness and damages claims over three patents that remain at issue in the firms' decade-long infringement battle over stent technology will be heard in separate trials by different juries, a judge has ruled, following a landmark $716 million settlement resolving more than a dozen of the companies' lawsuits.
Johnson & Johnson subsidiary Cordis' damages and willfulness claims over its Palmaz '762 and Gray '406 stent patents will be tried separately and before a different jury from the same...
